Empe Diagnostics
Empe Diagnostics is a privately held Swedish biotechnology company, founded in 2015 and based in Solna, that develops diagnostic solutions for infectious diseases with a focus on antimicrobial resistance, serving clinical and research buyers.
- Company typePrivate
- Founded2015
- HeadquartersSolna, Sweden
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Empe Diagnostics does
Empe Diagnostics is a privately held Swedish biotechnology company founded in 2015 and headquartered in Solna, Sweden. The company develops diagnostic solutions for infectious diseases, with a stated specialization in antimicrobial resistance (AMR)—a clinical problem in which pathogens evolve resistance to existing antibiotic therapies, increasing morbidity, mortality, and treatment cost. The company operates with a headcount band of 11–50 employees, consistent with an early-stage venture-backed diagnostics developer.
The company's disclosed capital history consists of three small equity rounds totaling approximately $4.48M between June 2018 and April 2020, led consistently by Sciety (a Swedish life sciences investment syndicate) with co-investment from Almi Invest. Leadership is anchored by founder and CEO Pavan Asalapuram and co-founder and Chairman Mats Nilsson, the latter associated with academic molecular diagnostics research at Stockholm University.
Specific product architecture, assay format (e.g., PCR, isothermal, sequencing-based), pricing model, customer segments, and revenue mechanics are not disclosed in the input data. As an AMR-focused diagnostics developer, the most plausible GTM model would be a B2B sale of kits, reagents, or instruments to clinical laboratories, hospital networks, and public-health buyers—but this is inferred, not stated. The company is pre-commercial or early-commercial based on its funding scale and headcount.
Empe Diagnostics firmographics
Firmographics- Name
- Empe Diagnostics
- Website
- https://empediagnostics.com
- Company type
- Private
- Founded year
- 2015
- Headcount range
- 11–50 employees
- Short description
- Empe Diagnostics is a privately held Swedish biotechnology company, founded in 2015 and based in Solna, that develops diagnostic solutions for infectious diseases with a focus on antimicrobial resistance, serving clinical and research buyers.
- Ownership category
- akta.pro rank
Empe Diagnostics industry classification
Industry- Product category
- Infectious Disease Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Microbiology & Infectious Disease Diagnostics (Culture/ID/AST) (HLAHAAAC)
- akta.pro secondary industries
- Infectious Disease POCT (Respiratory, STI, HIV, Sepsis) (HLAHAOAA), Hospital Epidemiology & Infection Prevention (HLAKAGAF), Microbiology & Infectious Disease Testing Laboratories (HLAFAMAD)
Keywords
Where Empe Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Solna
- HQ country
- Sweden
- HQ region
- Europe
Markets served
Empe Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Empe Diagnostics product offering
Product offeringCore offering
Empe Diagnostics develops and sells diagnostic solutions for infectious diseases, with a particular specialization in detecting antimicrobial resistance (AMR). The company provides diagnostic products that help healthcare professionals and laboratories identify pathogens and their resistance profiles to guide appropriate treatment decisions.
Differentiator
Problem solved
Functional benefit
Products and services
- Infectious Disease Diagnostic Solutions Diagnostic products and solutions designed to identify infectious disease pathogens and detect antimicrobial resistance, intended for clinical laboratories, hospitals, and healthcare institutions.
- Antimicrobial Resistance (AMR) Diagnostic Products Specialized diagnostic products targeting antimicrobial resistance detection, designed to help healthcare providers identify drug-resistant pathogens and guide appropriate antibiotic treatment.
Companies that use Empe Diagnostics
Customer profileIdeal customer profiles1 record
Empe Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Empe Diagnostics partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights3 records
Empe Diagnostics competitors and assessment
Company assessmentEmerging players
- Specific Diagnostics: Developer of rapid AST instruments using volatile metabolic profiling. Comparable as a small, growth-stage AMR-focused IVD company competing on AST speed.
- Resistell: Swiss developer of nanomotion-based rapid AST technology. Comparable as an emerging AMR diagnostics peer pursuing faster, phenotype-based susceptibility testing.
Direct peers
- T2 Biosystems: Developer of rapid molecular diagnostics for sepsis and other infectious diseases. Comparable as a small-cap molecular IVD company tackling infectious disease and resistance-related decision-making in hospital settings.
- Q-linea: Swedish infectious disease diagnostics company developing rapid AST solutions. Highly comparable on geography (Nordic biotech cluster), focus (rapid AST), and customer base (hospital microbiology labs).
- Accelerate Diagnostics: Specializes in rapid antimicrobial susceptibility testing and ID directly from clinical samples. Highly comparable as a focused AMR/ID IVD player pursuing faster alternatives to traditional culture-based workflows.
- OpGen (Curetis): Develops molecular diagnostics and bioinformatics for infectious disease and AMR surveillance. Comparable as a small-cap IVD player focused on rapid ID/AST and hospital infection prevention.
Regional players
- TATAA Biocenter: Swedish molecular diagnostics services and reagents provider closely linked to the Swedish qPCR/molecular diagnostics ecosystem. Comparable as a Sweden-based molecular diagnostics player in the same regional talent and customer network.
Broad incumbents
- bioMérieux: Global leader in clinical microbiology and infectious disease diagnostics, including antimicrobial susceptibility testing (VITEK). Directly comparable because it sells IVD solutions for ID/AST into the same hospital laboratory customers Empe targets.
- GenMark Diagnostics (Roche): Molecular multiplex diagnostics for infectious disease (ePlex). Comparable as a molecular infectious-disease IVD platform addressing hospital lab testing workflows for pathogen ID.
- Cepheid (Danaher): Operates the GeneXpert molecular diagnostics platform widely deployed for infectious disease testing. Comparable because it sets the performance/turnaround benchmark Empe must meet to win hospital lab adoption.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat2 records
Key risks6 records
Key highlights5 records
Customer concentration
Empe Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Empe Diagnostics leadership team
Management profileNumber of profiles
Profiles2 records
Empe Diagnostics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Empe Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Empe Diagnostics
What does Empe Diagnostics do?
Empe Diagnostics develops and sells diagnostic solutions for infectious diseases, with a particular specialization in detecting antimicrobial resistance (AMR). The company provides diagnostic products that help healthcare professionals and laboratories identify pathogens and their resistance profiles to guide appropriate treatment decisions.
When was Empe Diagnostics founded?
Empe Diagnostics was founded in 2015. It employs 11 to 50 people.
Where is Empe Diagnostics based?
Empe Diagnostics is headquartered in Solna, Sweden, in the Europe region.
Who are Empe Diagnostics's main competitors?
Emerging players on record are Specific Diagnostics and Resistell. Direct peers are T2 Biosystems, Q-linea, Accelerate Diagnostics and OpGen (Curetis). TATAA Biocenter is listed as a regional player. Broad incumbents are bioMérieux, GenMark Diagnostics (Roche) and Cepheid (Danaher).
Does Empe Diagnostics have an API?
No public API is recorded for Empe Diagnostics.
What industry is Empe Diagnostics in?
Empe Diagnostics's product category is Infectious Disease Diagnostics. Its primary akta.pro industry code is HLAHAAAC, Microbiology & Infectious Disease Diagnostics (Culture/ID/AST), with a secondary code of HLAHAOAA, Infectious Disease POCT (Respiratory, STI, HIV, Sepsis). Its NAICS code is 325413 and its SIC code is 2835.